Ketamine as a Novel Antidepressant for Treatment-Resistant Depression in Adolescents

Michael H. Bloch, MD, MS
Associate Professor • Director and Co-Founder, Pediatric Depression Clinic • Co-Director, T32 Postdoctoral Research Fellowship in Childhood Neuropsychiatric Disorders • Associate Program Director, Albert J. Solnit Integrated Training Program • Co-Director, Tic and OCD Program •  Child Study Center • Yale School of Medicine

Learning objectives:
Upon completion of this activity, participants will be able to:

• Identify two medications that have been approved for the treatment of depression in pediatric depression 
• Describe the indications, time course of response, and potential side effects of SSRI in pediatric populations 
• Describe the time course and magnitude of antidepressant effects of ketamine in adults with depression 
• Name three clinically important unanswered questions in pediatric depression psychopharmacology

----------

Child and Adolescent Psychiatry and Behavioral Sciences Grand Rounds presentations are for educational purposes and intended only for behavioral/mental health professionals and clinical providers.

Continuing education (CE) credit is available for physicians, psychologists, nurses, and therapists who participate in this activity.